Business Context and Reporting Period
This Form 8-K is filed by Lisata Therapeutics, Inc. (Lisata) on June 1, 2026. The report addresses a material development regarding a previously announced Agreement and Plan of Merger with Kuva Labs Inc. (Parent) and its subsidiary, Kuva Acquisition Corp. (Purchaser).
Key Financial Metrics
This filing is a Current Report regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document explicitly states that the tender offer has not yet commenced and provides no financial metrics for the reporting period.
Material Changes
- Delay in Tender Offer Commencement: Although an amendment to the Merger Agreement extended the obligation to commence the tender offer to June 1, 2026, Parent informed Lisata on the evening of May 31, 2026, that it will not commence the offer on June 1, 2026.
- Reason for Delay: Parent is currently negotiating with potential financing sources and evaluating the timing for the commencement of the offer.
- Uncertainty: There is no assurance as to when the tender offer will commence, if at all.
Outlook, Risks, and Management Commentary
Management Commentary: The filing serves as an informational update. It clarifies that this document is not an offer to purchase shares and that definitive tender offer materials (Schedule TO) and solicitation statements (Schedule 14D-9) will be filed only if and when the offer commences.
Risks and Contingencies: The filing highlights significant risks associated with the proposed acquisition, including:
- Failure of Parent to commence the tender offer promptly or at all.
- Failure to satisfy closing conditions within the expected timeframe.
- Potential termination of the Merger Agreement, which could trigger termination fees.
- Uncertainty regarding the number of shares stockholders will tender.
- Operational risks specific to Lisata, including clinical development efficacy, regulatory approval, and cash sufficiency.
Investor Verification Checklist
- Monitor for the filing of a Schedule TO (Tender Offer Statement) and Schedule 14D-9 (Solicitation/Recommendation Statement) to confirm if the offer has commenced.
- Verify the status of Parent's financing negotiations, as this is the stated cause for the delay.
- Review Lisata's most recent Form 10-K (for the year ended December 31, 2025) for current cash runway and financial health, as this 8-K contains no financial data.
- Check for any competing offers or legal proceedings that could impact the Merger Agreement.